80
Participants
Start Date
April 15, 2018
Primary Completion Date
June 30, 2024
Study Completion Date
June 30, 2024
Doxazosin Mesylate, Extended Release
Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).
Placebo
Placebo, or inactive pill.
San Francisco VA Medical Center, San Francisco
United States Department of Defense
FED
Northern California Institute of Research and Education
OTHER
San Francisco Veterans Affairs Medical Center
FED